Symthera, Inc. is a biopharmaceutical company whose mission is to develop treatments for Metastatic Cancer. Symthera’s focus is on the rapid development and commercialization of innovative pharmaceutical products for the treatment of Metastatic Cancer.
Targeted therapies have been shown to provide benefit to patients by selectively targeting disease-associated proteins. Overall impact on disease by such approaches has, however, failed to provide robust impact as single-agent therapies. Symthera has developed a proprietary approach to identify consensus amino acid sequences shared by, or unique to disease-associated proteins to validate disease-related targets and simultaneously identify drug leads that impact that network. By alignment of multiple sequences, Symthera's approach will disclose unique, cryptic consensus sequences between disease-associated proteins. Symthera has established an effective means to characterize target interaction profile and to identify peptide drug candidates via a proprietary microarray-based screening approach, coupled with high-efficiency peptide synthesis capabilities and characterization of disease impact early in the drug discovery process using animal models. Identification of agents that appropriately affect multiple targets is not readily addressed by traditional drug discovery approaches. Via Symthera's disease-network drug discovery approach, stretches of shared sequences provide an advanced starting point for identification of peptide drug candidates that impact the disease network rather than a single target. Peptide drugs have demonstrated efficacy on the market or in the clinic for a range of diseases and can be delivered by multiple routes including oral, intranasal, intramuscular and intrathecal administration. The approach is geared to generate well-characterized drug candidates with a high success rate and clear path to clinical and commercial application.
Symthera's drug leads, biological peptides, address the immediate shortcomings of existing medication in the following ways: Protein derivatives - Low toxicity natural products - High specificity therapeutics - Minimal side effects - Immune modulators - Inducers of immune tolerance. Symthera’s focus is on the rapid development and commercialization of innovative pharmaceutical products for the treatment of Metastatic Cancer.
Symthera is a drug discovery company with a unique technology platform capable of identifying novel treatments for diseases with unmet medical needs. Symthera is the first biotechnology company to apply the power of network theory to drug discovery and has pioneered a novel approach to modulating the immune network. Symthera has identified peptides motifs using systems biology approaches of sequence sharing patterns within and between cancer-associated proteins which contribute to the regulation of cell cycle progression.
Rose is a lawyer and entrepreneur, having earned her law degree from Osgoode Hall Law School in Toronto, Canada and was in private law practice. She was previously a co-founder of a leading provider of IP-based contact center technology where she served as Vice President Legal, General Counsel and Corporate Secretary.
Chai is a graduate of Ben Gurion University, Israel (Chemistry), Montreal University, Canada (Biochemistry) and The Weizmann Institute of Science, Israel (Life Sciences). Chai pioneered the concept of balance in the chemokine network and developed a biological infrastructure that has validated the concept in animal models of disease.
Professor of Cancer Medicine and Medical Oncology, Justin Stebbing specialises in a range of malignancies, their treatment with immunotherapy (breast, GI and lung and clinical trials), having originally trained in medicine at Trinity College Oxford. He is a Fellow of the Royal College of Physicians, the American Board of Internal Medicine and the Royal College of Pathologists, and sits on the advisory Boards of a number of international cancer committees. Other positions include Chair of the Irish Cancer Society oversight committee, Board of Directors Curemark, Chair of Scientific Advisory Boards Heat Biologics, Proton Partners, APIM Therapeutics, Imagen Biotech. In 2016 I was elected to be a Fellow of the American Society for Clinical Investigation.
Michael is Executive Chairman of Advanced Oncotherapy, an AIM-listed developer of next-generation Proton Beam Therapy technology, Chairman of Opiant Pharmaceuticals, a NASDAQ listed company, specialising in the treatment of Addictive Behaviors and currently serves on the Board of Overseers ( Emeritus ) of the Tufts University School of Medicine.
Mauerberger Prof. of Immunology, The Weizmann Institute of Science, Israel. Professor Cohen has made notable contributions to our understanding of immunology, in particular, autoimmunity and autoimmune disease.